{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 7.7844305, "regularMarketPrice": 1.8, "exchange": "NGM", "shortName": "EQRx, Inc.", "longName": "EQRx, Inc.", "messageBoardId": "finmb_650773385", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "bookValue": 2.733, "fiftyDayAverage": 1.8532, "fiftyDayAverageChange": -0.053200006, "fiftyDayAverageChangePercent": -0.028707106, "twoHundredDayAverage": 3.353525, "twoHundredDayAverageChange": -1.553525, "twoHundredDayAverageChangePercent": -0.46325135, "marketCap": 893005120, "forwardPE": -2.6470587, "priceToBook": 0.6586169, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.0 - Hold", "tradeable": false, "cryptoTradeable": false, "earningsTimestamp": 1683577800, "earningsTimestampStart": 1683577800, "earningsTimestampEnd": 1683577800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.35, "epsForward": -0.68, "epsCurrentYear": -0.6, "priceEpsCurrentYear": -2.9999998, "sharesOutstanding": 488603008, "firstTradeDateMilliseconds": 1622727000000, "priceHint": 4, "regularMarketChange": 0.13, "regularMarketTime": 1684180804, "regularMarketDayHigh": 1.8, "regularMarketDayRange": "1.67 - 1.8", "regularMarketDayLow": 1.67, "regularMarketVolume": 1254960, "regularMarketPreviousClose": 1.67, "bid": 0.0, "ask": 0.0, "bidSize": 22, "askSize": 31, "fullExchangeName": "NasdaqGM", "financialCurrency": "USD", "regularMarketOpen": 1.67, "averageDailyVolume3Month": 2195981, "averageDailyVolume10Day": 1607270, "fiftyTwoWeekLowChange": 0.21999991, "fiftyTwoWeekLowChangePercent": 0.13924044, "fiftyTwoWeekRange": "1.58 - 6.05", "fiftyTwoWeekHighChange": -4.25, "fiftyTwoWeekHighChangePercent": -0.7024793, "fiftyTwoWeekLow": 1.58, "fiftyTwoWeekHigh": 6.05, "marketState": "PRE", "displayName": "EQRx", "symbol": "EQRX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "50 Hampshire Street", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 315 2255", "website": "https://www.eqrx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 362, "companyOfficers": [{"maxAge": 1, "name": "Mr. Alexis A. Borisy A.M.", "age": 50, "title": "Founder & Exec. Chairman of Board of Directors", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Melanie I. Nallicheri", "age": 53, "title": "Pres, CEO, Principal Exec. & Financial Officer and Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 931750, "fmt": "931.75k", "longFmt": "931,750"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 75110, "fmt": "75.11k", "longFmt": "75,110"}}, {"maxAge": 1, "name": "Ms. Dina  Ciarimboli J.D.", "age": 53, "title": "Gen. Counsel & Corp. Sec.", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 628628, "fmt": "628.63k", "longFmt": "628,628"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 11430, "fmt": "11.43k", "longFmt": "11,430"}}, {"maxAge": 1, "name": "Mr. Robert  Forrester LL.B.", "age": 58, "title": "Co-Founder & Advisor", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Peter B. Bach M.D., MAPP", "age": 57, "title": "Co-Founder & Advisor", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sir Andrew  Dillon CBE", "title": "Co-Founder & Advisor", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Daniel  Hoey", "age": 55, "title": "Chief of Technical Operations", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Rona  Anhalt", "age": 57, "title": "Chief People Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Carlos  Garcia-Echeverria Ph.D.", "age": 57, "title": "Chief of RX Creation", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Christian  Antoni M.D., Ph.D.", "age": 60, "title": "Chief Global Devel. Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 6, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}